Clinical trials: Invasive Carcinoma
Lung Cancer, Non-Small Cell Lung Cancer
Is 3D Modeling From Non-contrast CT Accurate for Minimally Invasive Lung Segmentectomies ?
To assess the RELIABILITY in terms of accuracy of 3D-CT and 2D-CT reconstructions compared to intraoperative data regarding bronchovascular anatomy and tumor location.
- Trial name
- 3D-LS (NCT07234604)
- Testing
- Thoraco-abdomino-pelvic CT scan without and with contrast injection.
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Transitional Cell Carcinoma of Urinary Bladder
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.
The purpose of this study is to define the optimal management of localised transitional cell carcinoma (TCC) of the urinary bladder. The main objective is to evaluate whether chemoradiation is superior to radiotherapy alone.
- Trial name
- NCT00330499
- Testing
- Cisplatin, External beam radiation treatment
- Where
- 22 sites in Australia, New Zealand
- Volunteers
- 67 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Carcinoma in Situ, Non Muscle Invasive Bladder Cancer
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
This is a Phase II pilot study to explore the effect of intravesical TMX-101 in patients with CIS bladder cancer, as assessed by histology and cytology after TMX-101 treatment.
- Trial name
- NCT01731652
- Testing
- TMX-101
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Telormedix SA
Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone is a drug which blocks some effects of chemicals called beta-endorphins that are made in the body. Beta-endorphins can be made in response to stress, injury, and also pleasurable activities.
- Conditions
- Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma
- Trial name
- NCT02137252
- Testing
- Naltrexone, Sugar Pill
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Dana-Farber Cancer Institute
Non-muscle Invasive Bladder Cancer
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of intravesical cis-urocanic acid in patients with primary or recurrent non-muscle invasive bladder cancer.
- Trial name
- NCT01458847
- Testing
- cis-UCA solution
- Where
- 2 sites in Finland
- Volunteers
- 12 people
- Sponsor
- BioCis Pharma Ltd
Superficial Bladder Cancer
Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer
This protocol is evaluating efficacy and toxicity of three sequential whole bladder photodynamic treatment with Photofrin and red laser light (630 nm) in the management of superficial bladder cancer (non-muscle invasive) in those…
- Trial name
- NCT00322699
- Testing
- Whole bladder laser light treatment as an alternative to radical cystectomy, Photofrin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- North Florida/South Georgia Veterans Health System
Invasive Breast Carcinoma, Recurrent Breast Carcinoma
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
This randomized phase III trial studies tamoxifen citrate or letrozole together with bevacizumab to see how well it works compared with tamoxifen citrate or letrozole alone in treating women with stage IIIB or stage IV breast…
- Conditions
- Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT00601900
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Letrozole
- Where
- 522 sites in United States, Puerto Rico
- Volunteers
- 394 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Markers of Response to Intravesical Bladder Cancer Therapy
The goal of this laboratory research study is to see if researchers can predict whose cancer will stay in remission and whose will return in patients receiving treatment for bladder cancer.
- Trial name
- NCT01007058
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms
BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder Cancer
This observational study evaluates the urine test BladMetrix for monitoring bladder cancer recurrences in people with non muscle invasive bladder cancer (NMIBC) who are in follow-up after surgery.
- Conditions
- Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Bladder
- Trial name
- BladMetrix (NCT07511517)
- Testing
- BladMetrix urine test
- Where
- 6 sites in Norway
- Volunteers
- 500 people
- Sponsor
- Oslo University Hospital
Bladder Cancer, Metastatic Bladder Cancer
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
This is a pilot study of avelumab in patients with non-metastatic, muscle invasive bladder cancer who are eligible for radical cystectomy (RC), but are ineligible for cisplatin based neoadjuvant therapy.
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer
- Trial name
- NCT03498196
- Testing
- Avelumab
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Baylor College of Medicine
Breast Cancer
5 Years Follow-up With Adjuvant Therapy for Women With Breast Invasive Carcinoma
Non-persistence to adjuvant hormonal therapy for breast cancer at 5 years decrease its efficacy. The objective of this study is to know the women experience (persistence, treatment changes, quality of life) and its determinants…
- Trial name
- HACAMI (NCT02791750)
- Testing
- questionnary of quality of life
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut de Cancérologie de Lorraine
Muscle-Invasive Bladder Carcinoma
AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
AURORAX-0093A (AUR93A) is a pilot cohort observational study that will explore the use of urine and plasma glycosaminoglycans (GAGs) to prognosticate muscle-invasive bladder cancer (MIBC) patients elected for neo-adjuvant…
- Trial name
- AUR93A (NCT05028660)
- Testing
- GAG score
- Where
- 5 sites in Denmark, Italy and 1 more
- Volunteers
- 43 people
- Sponsor
- Elypta
Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC)
Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study
Despite increasing recognition of sexual dysfunction and sexual distress as important survivorship issues in oncology, research and clinical attention remain uneven across cancer types.
- Conditions
- Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC), Muscle-Invasive Bladder Carcinoma
- Trial name
- SPICE (NCT07339761)
- Testing
- Sexological Support
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
This clinical trial assesses whether a newly designed algorithm which looks at the genomic signature of each patient's tumor to predict their sensitivity to standard of care treatment verses being placed on a personally designed…
- Conditions
- Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT02276443
- Testing
- Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 798 people
- Sponsor
- M.D. Anderson Cancer Center
Muscle-Invasive Bladder Carcinoma
The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
The goal of this clinical trial is to evaluate the protective effect of metformin on nephrotoxicity of cisplatin in patients with bladder cancer.
- Trial name
- NCT06215976
- Testing
- Metformin Hydrochloride 500 MG
- Where
- Egypt
- Volunteers
- 78 people
- Sponsor
- Cairo University
Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
In this study, patients with BCC will be given neoadjuvant treatment with a drug called sonidegib. Sonidegib is a daily tablet usually given for BCC that cannot be removed by surgery or that has spread through the body.
- Conditions
- Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified, Skin Cancer, Invasive Carcinoma
- Trial name
- SONIB (NCT03534947)
- Testing
- Sonidegib, Imiquimod, Surgery
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Melanoma Institute Australia
Invasive Lobular and Ductal Carcinoma
Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)
Hypofractionated intraoperative boost (HIOB) is defined as hypofractionated WBRT (40.5 Gy in 2.7 Gy per fraction) preceded by an intraoperative boost to the tumor bed (10 Gy IOERT).
- Trial name
- NCT01295723
- Testing
- Hypofractionated Whole Breast Radiation Therapy, Intraoperative Electron Radiation Therapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- St. Joseph Hospital of Orange
Breast Cancer, Chronic Myeloproliferative Disorders
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00064311
- Testing
- ravuconazole
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Superficial Bladder Cancer
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
This Phase 2 study is designed to assess the efficacy and safety of INSTILADRIN (rAd-IFN with Syn3) when given intravesically to patients with high grade non-muscle invasive bladder cancer who are refractory to or have relapsed…
- Trial name
- NCT01687244
- Testing
- INSTILADRIN
- Volunteers
- 40 people
- Sponsor
- FKD Therapies Oy
Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Trial name
- NCT02140021
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- M.D. Anderson Cancer Center